Next dispatch cutoff Friday--:--:--

Compound reference

BPC-157 vs TB-500: sequence, mass and identity data compared

Published 2026-10-29 · updated 2026-10-29 · vendor-authored explanatory note

Short answer

BPC-157 and TB-500 are unrelated synthetic peptides that are often listed side by side. BPC-157 is a 15-residue peptide (GEPPPGKPADDAGLV, C62H98N16O22, 1419.5 g/mol, CAS 137525-51-0). TB-500 is the N-terminally acetylated 7-residue fragment Ac-LKKTETQ, residues 17-23 of thymosin beta-4 (C38H68N10O14, 889.0 g/mol, CAS 885340-08-9). Because their masses differ, an LC-MS identity check tells them apart immediately. Nothing on this page describes or supports any use in people or animals.

Catalog materials discussed on this page

Reference identity data from PubChem (computed values, retrieved 2026-10-29). Expected m/z values are calculated from PubChem average and monoisotopic masses. Not a statement about any catalog lot.
PropertyBPC-157TB-500
Origin of the sequencePartial sequence of a gastric-juice protein described as body protection compoundResidues 17-23 of thymosin beta-4 (the actin-binding motif LKKTETQ), N-terminally acetylated
SequenceGEPPPGKPADDAGLV (15 residues)Ac-LKKTETQ (7 residues)
Molecular formulaC62H98N16O22C38H68N10O14
Molecular weight (average)1419.5 g/mol889.0 g/mol
Monoisotopic mass1418.704888.492
CAS number137525-51-0885340-08-9
PubChem CID994195762707662
Expected [M+H]+ (monoisotopic)m/z 1419.71m/z 889.50
Expected [M+2H]2+ (monoisotopic)m/z 710.36m/z 445.25

Why the two are compared at all

The two names travel together because they are frequently sold as single vials and as combined blends. Chemically they have nothing in common: different parent proteins, different lengths, no shared sequence. Any comparison that matters at the bench is a comparison of identity data, purity data and handling, which is what the table above covers.

BPC-157 is a free-acid pentadecapeptide with a proline-rich N-terminal half (three consecutive prolines at positions 3-5) and an acidic Asp-Asp pair at positions 10-11. TB-500 is a short, strongly basic heptapeptide with two adjacent lysines and an acetylated N-terminus. Those features drive how each behaves in reversed-phase HPLC and in electrospray ionization.

How LC-MS tells them apart

In positive-mode electrospray, BPC-157 is usually seen as its singly and doubly protonated ions (about m/z 1420 and 711). TB-500, at 889 Da, gives an [M+H]+ near m/z 889-890 and an [M+2H]2+ near m/z 445. A sodium adduct [M+Na]+ about 22 units above [M+H]+ is common for both and is not evidence of a different compound.

A certificate that labels a mass spectrum as BPC-157 but shows its main peaks near 445 and 889, or the reverse, describes the wrong material or a mislabeled sample. That check takes seconds and needs no instrument, only the expected values. The LC-MS m/z calculator on this site prints them for any charge state.

  1. Match the observed m/z to the expected value for the stated charge state (within the lab's reported tolerance).
  2. Check whether the lab reports average or monoisotopic values; the difference is about 0.5-1 unit at this size.
  3. Adducts (+Na, +K) and in-source fragments are normal; an unexplained dominant peak is a question for the lab.

What HPLC purity does and does not say

HPLC-UV purity is the area of the main peak as a percentage of all detected peak area at the stated wavelength. It does not identify the peak (that is the job of the mass spectrum), and it does not report net peptide content: counter-ions such as acetate or trifluoroacetate and residual water are invisible to it. A certificate should therefore report purity, identity and measured quantity as three separate results.

Because TB-500 is small and very polar, it elutes early on many C18 gradients. An early, sharp main peak is not by itself a warning sign; a missing chromatogram is.

Documentation to request for either compound

Ask for a lot-specific certificate with the testing laboratory's name, the lot or batch number printed on the vial, the report date, an HPLC chromatogram with the purity figure, a mass spectrum with observed and expected values, and the measured quantity for the exact vial size. Published Vitality Chems lot reports for both compounds are listed on the testing page and can be looked up by lot number.

For TB-500 specifically, check which molecule the certificate's mass data support: the 889 Da fragment or the 4963 Da full-length thymosin beta-4. The companion guide explains why the two are confused and how to tell from a certificate.

Frequently asked

What is the difference between BPC-157 and TB-500?

They are unrelated peptides. BPC-157 is a 15-residue peptide (GEPPPGKPADDAGLV, 1419.5 g/mol). TB-500 is the acetylated 7-residue fragment Ac-LKKTETQ of thymosin beta-4 (889.0 g/mol).

What is the molecular weight of BPC-157?

1419.5 g/mol (PubChem CID 9941957, formula C62H98N16O22, CAS 137525-51-0).

What is the molecular weight of TB-500?

889.0 g/mol for the acetylated fragment Ac-LKKTETQ (PubChem CID 62707662, formula C38H68N10O14, CAS 885340-08-9). Full-length thymosin beta-4 is a different, 4963 g/mol molecule.

What m/z should an LC-MS identity check show for TB-500?

About m/z 889.5 for [M+H]+ and 445.3 for [M+2H]2+ (monoisotopic), with a sodium adduct near 911 often present.

Are BPC-157 and TB-500 approved medicines?

No. Materials sold for research use only are not approved drugs, are not manufactured or labeled for human or animal use, and are supplied only for qualified laboratory research.

References

  1. PubChem: BPC-157 (CID 9941957)Formula, molecular weight, monoisotopic mass, CAS.
  2. PubChem: TB-500 (CID 62707662)Formula, molecular weight, monoisotopic mass, CAS 885340-08-9.
  3. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012Identification of the TB-500 sequence as Ac-LKKTETQ.
  4. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017LC-MS characterization of BPC-157.
  5. Lian Z, et al. Characterization of synthetic peptide therapeutics using liquid chromatography-mass spectrometry: challenges, solutions, pitfalls. J Am Soc Mass Spectrom. 2021Charge states, adducts and LC-MS identity practice for synthetic peptides.